Default company panoramic image

Airway Therapeutics LLC

Developing recombinant human Surfactant Protein D for preterm babies to significantly improve outcomes and lower treatment costs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Cincinnati, OH, USA
  • Currency USD
  • Founded November 2008
  • Employees 2
  • Website

Company Summary

Airway Therapeutics, an Ohio LLC, is bringing to market a novel recombinant human surfactant protein, human Surfactant Protein D (rhSP-D), for use in a number of indications affecting the lung in preterm babies which will significantly improve clinical outcomes and drastically lower the costs after treatment without changing current hospital procedures.


  • Default avatar
    Joel Ira Ivers
    President and CEO

    Joel Ivers has over 30 years of experience in diagnostics, biotechnology, healthercare information technology, clinical research, medical devices, and pharmaceutics where he has developed extensive strategic marketing, licensing, business development, operations, and senior management expertise.


  • Default avatar
    David Willbrand, Thompson Hines

Previous Investors

  • Default avatar
    CincyTech USA
    Default avatar
    Cincinnati Childrens Hosptial Medical Center